east, and gastric) later this year or in 2015 as well as a potential filing in NSCLC in 2015 (based on phase II/III study in 2/3L PD-L1+ patients). Merck 8 Co., Inc. (MRK;MRK US) EYE Dec 2O13A 2O14E 2015E 2O16E 2017E EPS - Recurring ($) 01 (Mar) 0.85 0.88A 02 (Jun) 0.84 0.81 03 (Sep) 0.92 0.87 O4